Oncolytics Biotech Inc (ONC) - Total Assets

Latest as of June 2025: CA$19.97 Million CAD ≈ $14.45 Million USD

Based on the latest financial reports, Oncolytics Biotech Inc (ONC) holds total assets worth CA$19.97 Million CAD (≈ $14.45 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Oncolytics Biotech Inc - Total Assets Trend (1999–2024)

This chart illustrates how Oncolytics Biotech Inc's total assets have evolved over time, based on quarterly financial data. Also see ONC stock market capitalisation for the company's overall valuation and market capitalisation.

Oncolytics Biotech Inc - Asset Composition Analysis

Current Asset Composition (December 2024)

Oncolytics Biotech Inc's total assets of CA$19.97 Million consist of 93.5% current assets and 6.5% non-current assets. Review ONC liabilities breakdown to assess the company's total debt and financial obligations.

Asset Category	Amount (CAD)	% of Total Assets
Cash & Equivalents	CA$3.63 Million	79.0%
Accounts Receivable	CA$0.00	0.0%
Inventory	CA$0.00	0.0%
Property, Plant & Equipment	CA$1.31 Million	6.5%
Intangible Assets	CA$0.00	0.0%
Goodwill	CA$0.00	0.0%

Asset Composition Trend (1999–2024)

This chart illustrates how Oncolytics Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ONC share price today for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Oncolytics Biotech Inc's current assets represent 93.5% of total assets in 2024, an increase from 64.0% in 1999.
Cash Position: Cash and equivalents constituted 79.0% of total assets in 2024, up from 63.5% in 1999.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 35.0% in 1999.
Asset Diversification: The largest asset category is cash and equivalents at 79.0% of total assets.

Oncolytics Biotech Inc Competitors by Total Assets

Key competitors of Oncolytics Biotech Inc based on total assets are shown below.

Company	Country	Total Assets
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Dianthus Therapeutics Inc. NASDAQ:DNTH	USA	$1.21 Billion
Tango Therapeutics Inc NASDAQ:TNGX	USA	$1.07 Billion
Damora Therapeutics, Inc. NASDAQ:DMRA	USA	$543.64 Million
Apnimed, Inc. Common Stock NASDAQ:APMD	USA	$342.63 Million
Wecome Pharmaceutical Co Ltd SHE:300878	China	CN¥1.49 Billion
Tectonic Therapeutic, Inc. NASDAQ:TECX	USA	$246.58 Million
Relmada Therapeutics Inc NASDAQ:RLMD	USA	$235.36 Million

Oncolytics Biotech Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.88	4.99	9.09
Quick Ratio	2.88	4.99	9.09
Cash Ratio	0.00	0.00	0.00
Working Capital	CA$12.34 Million	CA$24.50 Million	CA$27.16 Million

Oncolytics Biotech Inc - Advanced Valuation Insights

This section examines the relationship between Oncolytics Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	23.41
Latest Market Cap to Assets Ratio	7.06
Asset Growth Rate (YoY)	-48.0%
Total Assets	CA$20.19 Million
Market Capitalization	$142.51 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Oncolytics Biotech Inc's assets at a significant premium (7.06x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: Oncolytics Biotech Inc's assets decreased by 48.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Oncolytics Biotech Inc (1999–2024)

The table below shows the annual total assets of Oncolytics Biotech Inc from 1999 to 2024.

Year	Total Assets	Change
2024-12-31	CA$20.19 Million ≈ $14.60 Million	-48.00%
2023-12-31	CA$38.82 Million ≈ $28.08 Million	+3.98%
2022-12-31	CA$37.33 Million ≈ $27.01 Million	-18.63%
2021-12-31	CA$45.88 Million ≈ $33.19 Million	+33.58%
2020-12-31	CA$34.35 Million ≈ $24.85 Million	+74.72%
2019-12-31	CA$19.66 Million ≈ $14.22 Million	+32.24%
2018-12-31	CA$14.87 Million ≈ $10.75 Million	-18.10%
2017-12-31	CA$18.15 Million ≈ $13.13 Million	+22.98%
2016-12-31	CA$14.76 Million ≈ $10.68 Million	-46.11%
2015-12-31	CA$27.38 Million ≈ $19.81 Million	+59.27%
2014-12-31	CA$17.19 Million ≈ $12.44 Million	-39.08%
2013-12-31	CA$28.22 Million ≈ $20.42 Million	+27.83%
2012-12-31	CA$22.08 Million ≈ $15.97 Million	-38.71%
2011-12-31	CA$36.02 Million ≈ $26.06 Million	-18.92%
2010-12-31	CA$44.43 Million ≈ $32.14 Million	+19.22%
2009-12-31	CA$37.27 Million ≈ $26.96 Million	+166.46%
2008-12-31	CA$13.99 Million ≈ $10.12 Million	-54.56%
2007-12-31	CA$30.78 Million ≈ $22.27 Million	-8.29%
2006-12-31	CA$33.57 Million ≈ $24.28 Million	-27.50%
2005-12-31	CA$46.29 Million ≈ $33.49 Million	+17.23%
2004-12-31	CA$39.49 Million ≈ $28.57 Million	+51.58%
2003-12-31	CA$26.05 Million ≈ $18.84 Million	+44.98%
2002-12-31	CA$17.97 Million ≈ $13.00 Million	-5.79%
2001-12-31	CA$19.07 Million ≈ $13.80 Million	-11.94%
2000-12-31	CA$21.66 Million ≈ $15.67 Million	+202.33%
1999-12-31	CA$7.16 Million ≈ $5.18 Million	--

About Oncolytics Biotech Inc

TO:ONC Canada Biotechnology

Market Cap

$1.08 Billion

CA$1.50 Billion CAD

Market Cap Rank

#17939 Global

#587 in Canada

Share Price

CA$14.90

Change (1 day)

+0.00%

52-Week Range

CA$14.90 - CA$14.90

All Time High

CA$18.60